Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | SLC2A1 | P11166 | 8/20 | 0.36 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4689868 | 0.88 | SLC2A1 (0.41) | GRIN1GRIN2BSLC2A1PAX8PTPN1 | |
| Trifluoroacetic Acid SCHEMBL4691189 | 0.88 | SLC2A1 (0.39) | GRIN1GRIN2BSLC2A1PAX8PTPN1 | |
| SCHEMBL4691391 | 0.87 | SLC2A1 (0.36) | GRIN1GRIN2BSLC2A1PAX8PTPN1 | |
| SCHEMBL4690295 | 0.84 | DHFR (0.37) | GRIN2BSLC2A1PAX8 | |
| Trifluoroacetic Acid SCHEMBL4691388 | 0.83 | SCN5A (0.38) | GRIN1GRIN2BSLC2A1PAX8PTPN1 | |
| SCHEMBL4688933 | 0.82 | SLC2A1 (0.40) | SLC2A1PTPN1 | |
| SCHEMBL4693979 | 0.82 | SLC2A1 (0.35) | GRIN1GRIN2BSLC2A1PAX8PTPN1 | |
| Trifluoroacetic Acid SCHEMBL4690935 | 0.81 | SLC2A1 (0.39) | GRIN1GRIN2BSLC2A1PAX8PTPN1 | |
| SCHEMBL4688280 | 0.78 | SLC2A1 (0.42) | SLC2A1PAX8 | |
| SCHEMBL4687979 | 0.77 | DHFR (0.46) | SLC2A1PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7262297-B2 | Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2007-08-28 | — | — | US | claimed |
| US-20040235872-A1 | Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors | BERTHEL STEVEN JOSEPH (US) | 2004-11-25 | — | — | US | claimed |
| EP-1628979-B1 | DIAMINOPYRROLOQUINAZOLINES COMPOUNDS AS PROTEIN TYROSINE PHOSPHATASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2008-03-19 | — | — | EP | disclosed |
| US-20070270445-A1 | Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors | BERTHEL STEVEN J | 2007-11-22 | — | — | US | disclosed |
| US-7262297-B2 | Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2007-08-28 | — | — | US | disclosed |
| US-20040235872-A1 | Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors | BERTHEL STEVEN JOSEPH (US) | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235872-A1 | Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors | PTPN5, PPP5C, PTP4A2 | GRIN1 2631/4885GRIN2B 3385/4885SLC2A1 271/4885 |
| US-20070270445-A1 | Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors | PTPN5, DUSP15, PPP5C | GRIN1 2853/4885GRIN2B 3532/4885SLC2A1 298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.